Basics of Chimeric Antigen Receptor CAR Immunotherapy

Basics of Chimeric Antigen Receptor  CAR  Immunotherapy
Author: Mumtaz Y. Balkhi
Publsiher: Academic Press
Total Pages: 92
Release: 2019-07-31
ISBN 10: 0128197471
ISBN 13: 9780128197479
Language: EN, FR, DE, ES & NL

Basics of Chimeric Antigen Receptor CAR Immunotherapy Book Review:

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols Provides unique authority as the editor has worked directly with CARs Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book
Author: Daniel W. Lee,Nirali N. Shah
Publsiher: Elsevier Health Sciences
Total Pages: 244
Release: 2019-11-30
ISBN 10: 0323755976
ISBN 13: 9780323755979
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book Book Review:

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer

Chimeric Antigen Receptor  CAR  T cell Immunotherapy for MUC1 positive Breast Cancer
Author: Artemis Gavriil
Publsiher: Unknown
Total Pages: 329
Release: 2018
ISBN 10:
ISBN 13: OCLC:1063625133
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor CAR T cell Immunotherapy for MUC1 positive Breast Cancer Book Review:

Chimeric Antigen Receptor T Cells

Chimeric Antigen Receptor T Cells
Author: Kamilla Swiech,Kelen Cristina Ribeiro Malmegrim,Virgínia Picanço-Castro
Publsiher: Humana
Total Pages: 274
Release: 2020-11-24
ISBN 10: 9781071601488
ISBN 13: 1071601482
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cells Book Review:

This volume provides comprehensive methods from expert scientists working in the Chimeric Antigen Receptor T Cell (CAR-T Cell) field. Chapters guide readers through the state-of-art of CAR-T cell technology, CAR design and vector production, CAR-T cell generation and manufacturing, CAR-T cell characterization, and quality control. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Chimeric Antigen Receptor T Cells: Development and Production aims to be useful in the production of CAR-T cells, especially for therapeutic purposes.

Developing Costimulatory Molecules for Immunotherapy of Diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases
Author: Manzoor Ahmad Mir
Publsiher: Academic Press
Total Pages: 322
Release: 2015-05-25
ISBN 10: 0128026758
ISBN 13: 9780128026755
Language: EN, FR, DE, ES & NL

Developing Costimulatory Molecules for Immunotherapy of Diseases Book Review:

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels

CAR T Cell Therapies for Non Hematopoietic Malignancies  Taking Off The Training Wheels
Author: Avery Dexter Posey, Jr.,John - Maher,Marcela V. Maus
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2020-04-24
ISBN 10: 2889636879
ISBN 13: 9782889636877
Language: EN, FR, DE, ES & NL

CAR T Cell Therapies for Non Hematopoietic Malignancies Taking Off The Training Wheels Book Review:

Chimeric antigen receptor (CAR) T cell therapies for leukemia (e.g. tisagenlecleucel) and lymphoma (e.g. axicabtagene ciloleucel) have recently received regulatory approval in the United States. Phase I/II trials have demonstrated complete remission of refractory or relapsed tumors in 50% - 94% patients. However, the clinical successes of engineered T cells for the treatment of solid malignancies have thus far been few and far between. Furthermore, several instances of severe and lethal toxicities have arisen due to on-target, off-tumor recognition of antigen by T cell products. Recent advances in phase I trials for solid tumors, as well as in pre-clinical models, have revealed several variables that will be important to consider for the successful use of CAR-T cells in treating solid tumors. These variables include (i) regional versus systemic delivery; (ii) scFv versus ligand interactions; (iii) antigen loss versus escape; (iv) epitope spreading and (v) checkpoint expression on immune cells or tumor cells. Also, there remains outstanding mechanistic questions related to why differences exist in the persistence and tonic signaling of second-generation CD28 versus 4-1BB co-stimulated CAR-T cells. In addition, we are now learning the roles of lympho-depleting regimens (and associated toxicities) in modifying the persistence of engineered T cell therapies. A more comprehensive view of CAR-T cell strategies and important advances, both of pre-clinical and clinical evaluations, in solid tumors is necessary to drive these therapies forward.

Immunotherapy Using Chimeric Antigen Receptor Macrophage

Immunotherapy Using Chimeric Antigen Receptor Macrophage
Author: Peng Fei Huang
Publsiher: Unknown
Total Pages: 44
Release: 2019
ISBN 10:
ISBN 13: OCLC:1089833443
Language: EN, FR, DE, ES & NL

Immunotherapy Using Chimeric Antigen Receptor Macrophage Book Review:

Chimeric antigen receptor (CAR) T cell immunotherapy has become one of the most prominent and leading cancer therapies due to its remarkable success in targeting hematological malignancies. Unfortunately, CAR-T cell immunotherapy has not had the same amount of success in solid tumors due to the challenging tumor's immunosuppressive microenvironment. Therefore, we hypothesize the use of macrophages as a vessel for CAR immunotherapy due to their associate with tumors as TAMs and also the tumors ability to secrete various chemokines that can attract myeloid cells to the tumor site. THP-1 a monocytic cell line that represents a monocyte/macrophage model was transduced with an anti-CD19 scFv CAR construct. K562 a leukemia cell line that represents hematological malignancies and H460 a lung cancer cell line that represents solid tumors were transduced to overexpress the surface marker CD19. THP-1 clones expressing the anti-CD19 CAR construct were cocultured with the two tumor cell lines, which demonstrated the ability of the THP-1 CARs to specifically targeted and lysis the tumor cells that overexpressed the CD19 surface marker. Upon CAR activation, THP-1 cells were polarized towards the M1 classical activated phenotype due to the increase in expression of TNF-[alpha], IL-1[beta], IL-6, IL-12[beta], CXCl10, HLA-DR, and CD86. Additionally, THP-1 cells did not show any change in the M2 alternative activated markers of IL10, TFG[beta], CCL18, CCL22, CD206, and CD204 to suggest polarization towards the M2 phenotype. As a result, this study validates the proof of concept that macrophages could potentially be a vessel for CAR immunotherapy.

Immunotherapy

Immunotherapy
Author: Krassimir Metodiev
Publsiher: BoD – Books on Demand
Total Pages: 414
Release: 2017-04-26
ISBN 10: 9535131052
ISBN 13: 9789535131052
Language: EN, FR, DE, ES & NL

Immunotherapy Book Review:

This is another attempt of InTechOpen to continue the dissemination of international knowledge and experience in the field of immunology. The present book includes a number of modern concepts of specialists and experts in the field of immunotherapy, covering the major topics and analyzing the history, current stage, and future ideas of application of modern immunomodulation. It is always a benefit, but also a compliment, to gather a team of internationally distinguished authors and to motivate them to reveal their expertise for the benefit of medical science and health practice. On behalf of all readers, immunologists, immunogeneticists, biologists, oncologists, microbiologists, virologists, hematologists, chemotherapists, health-care experts, as well as students and medical specialists, also on my personal behalf, I would like to extend my gratitude and highest appreciation to InTechOpen for giving me the unique chance to be the editor of this exclusive book.

Chimeric Antigen Receptor T Cell Therapy for the Community Oncologist

Chimeric Antigen Receptor T   Cell Therapy for the Community Oncologist
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2016
ISBN 10:
ISBN 13: OCLC:1053694839
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapy for the Community Oncologist Book Review:

Abstract : The field of cancer immunotherapy has rapidly progressed in the past decade as several therapeutic modalities have entered into the clinic. One such immunotherapy that has shown promise in the treatment of cancer is the use of chimeric antigen receptor (CAR)‐modified T lymphocytes. CARs are engineered receptors constructed from antigen recognition regions of antibodies fused to T‐cell signaling and costimulatory domains that can be used to reprogram a patient's T cells to specifically target tumor cells. CAR T‐cell therapy has demonstrated sustained complete responses for some patients with advanced leukemia, and a number of CAR therapies are being evaluated in clinical studies. CAR T‐cell therapy‐associated toxicities, including cytokine release syndrome, macrophage activation syndrome, and tumor lysis syndrome, have been observed and effectively managed in the clinic. In patients with significant clinical responses, sustained B‐cell aplasia has also been observed and is a marker of CAR T‐cell persistence that might provide long‐term disease control. Education on CAR T‐cell therapy efficacy and safety management is critical for clinicians and patients who are considering this novel type of treatment. In the present report, the current landscape of CAR T‐cell therapy, the effective management of patients undergoing treatment, and which patients are the most suitable candidates for current trials are discussed. Implications for Practice: The present report describes the current status of chimeric antigen receptor (CAR) T lymphocytes as an immunotherapy for patients with relapsed or refractory B‐cell malignancies. CAR T cells targeting CD19, a protein expressed on many B‐cell malignancies, typically induce high complete response rates in patients with B‐cell leukemia or lymphoma who have very limited therapeutic options. Recent clinical trial results of CD19 CAR T‐cell therapies and the management of CAR T‐cell‐associated adverse events are discussed. The present report will therefore inform physicians regarding the efficacy and safety of CAR T cells as a therapy for B‐cell malignancies. Abstract : An immunotherapy that has shown promise in cancer treatment is chimeric antigen receptor‐modified (CAR‐modified) T lymphocytes. CARs are engineered receptors constructed from antigen recognition regions of antibodies fused to T‐cell signaling and costimulatory domains that reprogram a patient's T cells to specifically target tumor cells. The current landscape of CAR T‐cell therapy, effective management of patients undergoing treatment, and the most suitable candidates for current trials are discussed.

Fast Facts CAR T Cell Therapy

Fast Facts  CAR T Cell Therapy
Author: R.J. Buka,A.J. Kansagra
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 72
Release: 2021-01-26
ISBN 10: 3318067423
ISBN 13: 9783318067422
Language: EN, FR, DE, ES & NL

Fast Facts CAR T Cell Therapy Book Review:

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions

Cancer Immunosurveillance

Cancer Immunosurveillance
Author: Alejandro López-Soto,Alicia R. Folgueras
Publsiher: Humana Press
Total Pages: 363
Release: 2018-11-22
ISBN 10: 9781493988846
ISBN 13: 1493988840
Language: EN, FR, DE, ES & NL

Cancer Immunosurveillance Book Review:

This volume explores the latest techniques used to study tumor immunology. The chapters in this book detail methodologies for functional analysis and expansion of T lymphocytes for cancer research. The chapters also cover topics such as how single-cell RNA-sequencing can be exploited to dissect immune cell heterogeneity and precursors; isolating and expanding natural killer (NK) cells; evaluating NK cell-mediated anti-tumor killing activity in vitro; immunosurveillance orchestrated by specific immune subsets; use of HLA peptidomics for cancer-exome based identification of tumor neo-antigens; gold standard assessment of immunogenic cell death in oncological mouse models and methods to look at the therapeutic relevance of immune modulation in cancer. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and thorough, Cancer Immunosurveillance: Methods and Protocols is a valuable resource to aid researchers in better understanding and experimenting in this exciting and developing field.

Translational Immunotherapy of Brain Tumors

Translational Immunotherapy of Brain Tumors
Author: John H. Sampson
Publsiher: Academic Press
Total Pages: 404
Release: 2017-02-06
ISBN 10: 0128026251
ISBN 13: 9780128026250
Language: EN, FR, DE, ES & NL

Translational Immunotherapy of Brain Tumors Book Review:

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas Edited by a prominent neurosurgeon with contributions by leading researchers in the field Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors

Developments in T Cell Based Cancer Immunotherapies

Developments in T Cell Based Cancer Immunotherapies
Author: Paolo A. Ascierto,David F. Stroncek,Ena Wang
Publsiher: Humana Press
Total Pages: 305
Release: 2015-11-26
ISBN 10: 3319211676
ISBN 13: 9783319211671
Language: EN, FR, DE, ES & NL

Developments in T Cell Based Cancer Immunotherapies Book Review:

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book
Author: Daniel W. Lee,Nirali N. Shah
Publsiher: Elsevier Health Sciences
Total Pages: 244
Release: 2019-11-30
ISBN 10: 0323755976
ISBN 13: 9780323755979
Language: EN, FR, DE, ES & NL

Chimeric Antigen Receptor T Cell Therapies for Cancer E Book Book Review:

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Immunotherapy in Translational Cancer Research

Immunotherapy in Translational Cancer Research
Author: Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran
Publsiher: John Wiley & Sons
Total Pages: 312
Release: 2018-05-01
ISBN 10: 1118123220
ISBN 13: 9781118123225
Language: EN, FR, DE, ES & NL

Immunotherapy in Translational Cancer Research Book Review:

A guide to state-of-the-art cancer immunotherapy in translational cancer research A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues. Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and: Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care Filled with the concepts, examples, and approaches for developing individualized therapy Explores the breath of treatments that reflect the complexity of the immune system itself Includes contributions from a panel international experts in the field of immunotherapy Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.

Immune Regulation

Immune Regulation
Author: Marc Feldmann,N. A. Mitchison
Publsiher: Springer Science & Business Media
Total Pages: 392
Release: 2012-12-06
ISBN 10: 1461249961
ISBN 13: 9781461249962
Language: EN, FR, DE, ES & NL

Immune Regulation Book Review:

Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs.

Hematopoietic Cell Transplantation for Malignant Conditions

Hematopoietic Cell Transplantation for Malignant Conditions
Author: Qaiser Bashir,Mehdi Hamadani
Publsiher: Elsevier Health Sciences
Total Pages: 438
Release: 2019-02-14
ISBN 10: 0323568033
ISBN 13: 9780323568036
Language: EN, FR, DE, ES & NL

Hematopoietic Cell Transplantation for Malignant Conditions Book Review:

Get a quick, expert overview of hematologic and non-hematologic malignancies for which hematopoietic cell transplantation is a treatment option. Drs. Qaiser Bashir and Mehdi Hamadani provide easy-to-find information on basic science of hematopoietic cell transplantation, pharmacology, workflows and procedures, possible complications and side effects, in addition to the role of HCT in conjunction with clinical cellular therapy. Discusses high-dose chemotherapeutic regimens and radiation therapy, patient and donor selection and workup, as well as other key aspects of hematopoietic cell transplantation. Includes practical information on complications, infectious disease, and special populations such as patients with HIV infection. Consolidates today’s available information in this fast-changing area into one convenient resource.

The Basics of Cancer Immunotherapy

The Basics of Cancer Immunotherapy
Author: Haidong Dong,Svetomir N. Markovic
Publsiher: Springer
Total Pages: 160
Release: 2018-01-05
ISBN 10: 3319706225
ISBN 13: 9783319706221
Language: EN, FR, DE, ES & NL

The Basics of Cancer Immunotherapy Book Review:

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.

Cell and Gene Therapies

Cell and Gene Therapies
Author: Miguel-Angel Perales,Syed A. Abutalib,Catherine Bollard
Publsiher: Springer
Total Pages: 288
Release: 2018-11-27
ISBN 10: 3319543687
ISBN 13: 9783319543680
Language: EN, FR, DE, ES & NL

Cell and Gene Therapies Book Review:

In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.

Second Generation Cell and Gene Based Therapies

Second Generation Cell and Gene Based Therapies
Author: Alain Vertes,Nathan J. Dowden,Devyn Smith,Nasib Qureshi
Publsiher: Academic Press
Total Pages: 846
Release: 2020-02-07
ISBN 10: 0128120339
ISBN 13: 9780128120330
Language: EN, FR, DE, ES & NL

Second Generation Cell and Gene Based Therapies Book Review:

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products. The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization "Perspectives" section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies